A risk score based on multiple genetic differences, or polygenic test, predicted significantly more cases of early heart disease than standard tests for single genetic defects. The polygenic test predicted a high risk for early-onset heart disease in 1 out of 53 individuals, compared to 1 in 256 for the most frequent single genetic defect.
Multiple Sclerosis is a chronic inflammatory disease of the central nervous system, in which the immune cells attack myelin sheaths. Regeneration of myelin sheaths is necessary for patients to recover from MS relapses. Nevertheless, the ability to regenerate decreases with age.
Given the ever-increasing obesity epidemic, researchers have discovered a promising developing drug that has been shown to selectively shrink excess fat by increasing fat cell metabolism. The drug significantly reduces body weight and blood cholesterol levels without lowering food intake in obese mice, according to a recent study.
In a direct comparison study, researchers have added to evidence that a newer method of calculating so-called 'bad cholesterol' levels in the blood is more accurate than the older method in people who did not fast before blood was drawn.
Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases. For multiple sclerosis, specifically, increasing cholesterol synthesis gene expression in astrocytes of the spinal cord can be a pathway to repair nerves that affect walking.
Substituting one to two servings of animal proteins with plant proteins every day could lead to a small reduction in the three main cholesterol markers for cardiovascular disease prevention, a new study suggests.
New research explains how an enzyme acts as a kind of thermostat that responds to and adjusts levels of cholesterol in the cell. This insight could lead to new strategies for combating high cholesterol.
We can add one more thing to the list of traits affected by genetics: how our bodies respond to a particular diet. Research in animal models with different genetics shows that one diet really doesn't fit all, and what works for some may not be best for others, according to a new study.
Heart disease and fatty clogs in the arteries go hand in hand. But new evidence suggests the fatty molecules might come not only from what you eat, but from the bacteria in your mouth, scientists report. The research may explain why gum disease is associated with heart trouble.
Tofu sausages on the barbecue, followed by cake made with bananas instead of eggs? There is no doubt that the vegan diet is in vogue. Alongside the proven positive effects on health, however, there are also risks.
Medical researchers have illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, narrow range. Known as Nrf1, it both senses and responds to excess cholesterol, and could represent a potential new therapeutic target in a multitude of diseases where cholesterol metabolism is disrupted.
LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease.
After decades of individual attempts to identify the structure of the main building block of HDL (high-density lipoproteins), the so-called 'good' cholesterol that associates with protection from cardiovascular disease, a research team representing eight academic institutions across the US and Australia has come to agreement on a predictive model.
If you have a heart attack or stroke, it's important to get your 'bad' cholesterol measured by your doctor on a follow up visit. Researchers have found that one step is significantly associated with a reduced risk of suffering another serious cardiovascular episode.
In the largest study of its kind, less than half of patients prescribed the new class of cholesterol drugs, PCSK9 inhibitors, received insurance approval even if patients had atherosclerotic cardiovascular disease (plaque build-up of the arteries) or markedly elevated bad cholesterol. The most significant factor associated with approval was insurance type, with Medicare patients more likely to be approved than those with private insurance.